AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
26. Januar 2023 07:00 ET
|
AC Immune SA
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response...
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
23. November 2022 07:30 ET
|
AC Immune SA
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and...
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease
19. Oktober 2020 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action
22. Mai 2018 08:02 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference
08. November 2017 08:12 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting
23. August 2017 09:45 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference
03. April 2017 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, April 03, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...